UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 6, 2008
Obagi Medical Products, Inc.
(Exact name of registrant as specified in its charter)
001-33204
(Commission File Number)
| Delaware | | 22-3904668 |
(State or other jurisdiction of incorporation) | | (I.R.S. Employer Identification No.) |
3760 Kilroy Airport Way, Suite 500, Long Beach, CA 90806
(Address of principal executive offices, with zip code)
(562) 628-1007
(Registrant’s telephone number, including area code)
310 Golden Shore, Suite 100, Long Beach, CA 90802
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| | o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On November 6, 2008, Obagi Medical Products, Inc. issued a press release announcing financial results for the three and nine months ended September 30, 2008. A copy of the press release is attached hereto as Exhibit 99.1, which is incorporated herein by reference.
The information furnished herewith pursuant to Item 2.02 of this Current Report and in Exhibit 99.1 hereto shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 2.02 and in Exhibit 99.1 hereto shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
| Exhibit Number | | Description |
| 99.1 | | Press Release of Obagi Medical Products, Inc. dated November 6, 2008 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | OBAGI MEDICAL PRODUCTS, INC. |
| | | |
| Date: November 6, 2008 | By: | /s/ PRESTON S. ROMM |
| | | Preston S. Romm |
| | | Chief Financial Officer |
| Contact: | | |
| Preston Romm | | Or: |
| CFO, EVP of Finance, Operations and Administration | | Ina McGuinness/Lena Adams |
| Obagi Medical Products, Inc. | | ICR, Inc. |
| 562.628.1007 | | 310.954.1100 |
OBAGI MEDICAL PRODUCTS REPORTS
THIRD QUARTER 2008 FINANCIAL RESULTS
Long Beach, Calif. — November 6, 2008 — Obagi Medical Products, Inc. (NASDAQ: OMPI), a leader in topical aesthetic and therapeutic skin health systems, today reported financial results for the third quarter and nine months ended September 30, 2008.
Despite the overall weakness in U.S. consumer spending and confidence, which has had a significant impact on the market for aesthetic procedures, net sales for the third quarter of 2008 were $26.0 million, compared with $26.3 million in the third quarter of 2007, with domestic and international sales representing 84% and 16% of sales, respectively.
Gross margin percentage was 80.3% in the third quarter of 2008, compared with 82.5% in the same quarter last year, primarily as a result of lower license fees and additional promotions.
Selling, general and administrative expenses increased $1.4 million to $15.0 million, with cost cutting programs more than offset by expenses associated with the SoluCLENZ Rx Gel™ launch and support, the direct-to-customer (DTC) awareness campaign and double rent paid during the quarter in conjunction with the Company’s move to new headquarters. As anticipated, these expenses amounted to $1.6 million on a pre-tax basis, or $0.04 per diluted share.
Net interest income for the third quarter amounted to $63,000, compared to net interest expense of $355,000 during the same quarter last year. This improvement of $418,000 was due to positive cash flow and paying off outstanding debt.
Net income was $2.9 million, or $0.13 per diluted share, versus $3.9 million, or $0.18 per diluted share, for the third quarter of 2007.
Highlights from the Company’s third quarter and the subsequent weeks include:
| · | Signed new international distribution agreements for China and Australia, with several new agreements pending; |
| · | Established 294 new physician accounts and increased active accounts as of September 30, 2008 to more than 5,600, up 12% from a year ago; |
| · | Expanded the Company’s domestic sales force to 133 people, up from 130 in mid-August 2008; |
| · | Launched SoluCLENZ Rx Gel, the only prescription “solubilized” benzoyl peroxide (BPO) gel for the treatment of acne, marking Obagi’s entry into the Rx channel. The initial net sales from SoluCLENZ Rx Gel recognized based on actual prescriptions totaled $25,000 since the soft launch in September; |
| · | Presented three posters at the Summer American Academy of Dermatology meeting that demonstrated greater efficacy in the treatment of mild to moderately severe acne vulgaris at early intervals up to six weeks for Obagi’s solubilized BPO formulation (CLENZIderm M.D.™ and SoluCLENZ Rx Gel) compared to a leading BPO/Clindamycin drug combination, without the concerns associated with antibiotic resistance; |
| · | Published a study of Obagi’s copper-zinc malonate eye treatment ELASTIderm™ in the September 2008 issue of Experimental Dermatology, a premier journal of investigative dermatology. The results of the study suggest that six weeks of treatment with ELASTIderm can enhance the biosynthesis of elastin in skin; and |
| · | Announced positive study results at the Fall Clinical Dermatology Conference showing that use of Obagi’s ELASTIderm™ Décolletage System is highly effective in improving photodamaged skin of the chest and neck in as early as two weeks. |
Chief Executive Officer, Steve Carlson, stated, “Given the current turbulent economic conditions and our seasonally weakest time of the year, we are pleased with our overall third quarter financial performance. While the consumer environment has been deteriorating and the worldwide economy remains unstable, our revenue was flat compared to last year. We will continue to take actions to improve operating efficiencies and financial discipline and make adjustments to our spending levels as necessary to improve upon our proven track record of profitability.”
“More importantly, Obagi remains an industry leader. Looking at our opportunities, we will continue our strategy of launching at least two new product innovations each year and 2009 will be no exception. We are also enthusiastic about the potential for growth for our international business. While this remains a smaller portion of our revenue, we are encouraged by progress in key geographies.”
Results for the First Nine Months of 2008
For the first nine months of 2008, compared with the first nine months of 2007:
| · | Net sales were $79.2 million, an increase of 5%, compared with $75.4 million; |
| · | Operating income declined 13% to $17.1 million, compared with $19.7 million; |
| · | Net income was $10.4 million, or $0.46 per diluted share, compared with net income of $10.7 million, or $0.49 per diluted share; |
| · | Gross margin percentage was 81.2%, compared with 82.6%; and |
| · | Net interest income was $186,000, compared with net interest expense of $2.0 million, resulting from the elimination of outstanding debt. |
The above operating income and earnings per diluted share through September 2008 included expenses associated with the SoluCLENZ Rx Gel launch and support, the DTC awareness campaign and double rent, which in aggregate amounted to $1.9 million on a year to date pre-tax basis, or an EPS impact of $0.05 per diluted share.
Strengthened Balance Sheet
As of September 30, 2008, the Company was debt free with cash and cash equivalents totaling $24.4 million, compared with $14.1 million at December 31, 2007. Working capital totaled $46.4 million and stockholders’ equity totaled $62.0 million as of September 30, 2008. This compares with $34.2 million in working capital and $49.7 million in stockholders’ equity as of December 31, 2007.
Revisions to Financial Guidance
The Company is revising guidance for the fourth quarter taking into consideration the continuing deterioration in the economy and its effect on strategic investments that it previously thought would create growth opportunities in the fourth quarter. As a result of the changes in the economy and its plans to continue to invest in strategic growth opportunities, the Company now expects the fourth quarter revenue to be in the range of $26.0 to $27.0 million, with EPS of $0.12 to $0.14, down from the previously guided $31.0 to $33.0 million and EPS of $0.26 to $0.29. This represents a flat to 4% decline in year over year revenue.
Conference Call Information
Obagi’s management will host a conference call to discuss the Company's financial performance today at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). Investors interested in participating in the live call can dial (800) 762-8908 from the U.S. International callers can dial (480) 629-9031. A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, November 20, by dialing (800) 406-7325 from the U.S., or (303) 590-3030 for international callers and entering confirmation code 3932987. There also will be a simultaneous webcast that will be archived for 30 days on the Investor Relations section of the Company’s web site at www.obagi.com.
About Obagi Medical Products, Inc. (www.obagi.com)
Obagi Medical Products develops and commercializes skin health products for the dermatology, plastic surgery, and related aesthetic markets. Using its Penetrating Therapeutics™ technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including chloasma, melasma, senile lentigines, acne vulgaris and sun damage. Obagi's skin care product introductions are as follows: Obagi Nu-Derm™, 1988; Obagi-C Rx™ (the only prescription-strength vitamin C and hydroquinone system), 2004; Obagi Professional-C™ (a line of highly stable vitamin C serums), 2005; Obagi Nu-Derm™ Condition and Enhance for use with cosmetic procedures, 2006; Obagi ELASTIderm™ eye treatment and Obagi CLENZIderm M.D.™ acne therapeutic systems, 2007; a formulation of CLENZIderm M.D.™ Systems for normal to dry skin, June 2007; ELASTIderm™ Décolletage System, January 2008 and SoluCLENZ Rx Gel™, August 2008.
Forward Looking Statements
There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should," "potential," "anticipates," "plans," or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the current and continued deterioration in the global
economy, intense competition our products face and will face in the future, the level of market acceptance of our products, including SoluCLENZ Rx Gel, the possibility that our products could be rendered obsolete by technological or medical advances, the possibility that we may become involved in intellectual property claims and litigation that could adversely affect the profitability of or our ability to sell our products, the possibility that our products may cause undesirable side effects and the fact that our ability to commercially distribute our products may be significantly harmed if the regulatory environment governing our products changes. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Obagi Medical Products does not intend to update this information.
###
| Obagi Medical Products, Inc. | |
| Condensed Consolidated Balance Sheets | |
| (Dollars in thousands, except share and per share amounts) | |
| | | | | | | | |
| | September 30, | | December 31, |
| | 2008 | | 2007 |
| Assets | | (unaudited) | | | | | |
| Current assets | | | | | | | |
Cash and cash equivalents | | $ | 24,373 | | | | $ | 14,054 | |
Accounts receivable, net | | | 18,567 | | | | | 17,370 | |
Accounts receivable from related parties, net | | | 794 | | | | | 982 | |
Inventories, net | | | 7,826 | | | | | 6,047 | |
Prepaid expenses and other current assets | | | 5,641 | | | | | 5,782 | |
Total current assets | | | 57,201 | | | | | 44,235 | |
| Property and equipment, net | | | 4,231 | | | | | 2,759 | |
| Goodwill | | | 4,629 | | | | | 4,629 | |
| Intangible assets, net | | | 5,417 | | | | | 5,760 | |
| Other assets | | | 2,247 | | | | | 2,380 | |
Total assets | | $ | 73,725 | | | | $ | 59,763 | |
| Liabilities and Stockholders’ Equity | | | | | | | | | |
Current liabilities | | | | | | | | | |
Accounts payable | | $ | 7,566 | | | | $ | 6,664 | |
Current portion of long-term debt | | | 47 | | | | | 54 | |
Accrued liabilities | | | 3,234 | | | | | 3,274 | |
Total current liabilities | | | 10,847 | | | | | 9,992 | |
| Long-term debt | | | 24 | | | | | 42 | |
| Other long-term liabilities | | | 904 | | | | | - | |
Total liabilities | | | 11,775 | | | | | 10,034 | |
| Commitments and contingencies | | | | | | | | | |
| Stockholders’ equity | | | | | | | | | |
Common stock, $.001 par value; 100,000,000 shares authorized, 22,691,238 | | | | | | | | | |
and 22,653,349 shares issued and 22,670,460 and 22,643,564 shares | | | | | | | | | |
outstanding at September 30, 2008 and December 31, 2007, respectively | | | 23 | | | | | 23 | |
Additional paid-in capital | | | 57,626 | | | | | 55,805 | |
Accumulated earnings (deficit) | | | 4,373 | | | | | (6,031 | ) |
Accumulated other comprehensive loss | | | (72 | ) | | | | (68 | ) |
Total stockholders’ equity | | | 61,950 | | | | | 49,729 | |
Total liabilities and stockholders’ equity | | $ | 73,725 | | | | $ | 59,763 | |
| Obagi Medical Products, Inc. | |
| Condensed Consolidated Statements of Income | |
| (Dollars in thousands, except share and per share amounts) | |
| | | | | | | | | | | | | | | | |
| | Three months ended September 30, | | Nine months ended September 30, |
| | 2008 | | 2007 | | 2008 | | 2007 |
| | | (unaudited) | | | | (unaudited) | |
| | | | | | | | | | | | | | | | |
| Net sales | | $ | 26,012 | | | | $ | 26,281 | | | | $ | 79,158 | | | | $ | 75,394 | |
| Cost of sales | | | 5,114 | | | | | 4,604 | | | | | 14,888 | | | | | 13,125 | |
Gross profit | | | 20,898 | | | | | 21,677 | | | | | 64,270 | | | | | 62,269 | |
| Selling, general and administrative expenses | | | 14,985 | | | | | 13,610 | | | | | 43,260 | | | | | 38,446 | |
| Research and development expenses | | | 1,155 | | | | | 1,355 | | | | | 3,872 | | | | | 4,121 | |
Income from operations | | | 4,758 | | | | | 6,712 | | | | | 17,138 | | | | | 19,702 | |
| Interest income | | | 91 | | | | | - | | | | | 279 | | | | | 100 | |
| Interest expense | | | (28 | ) | | | | (355 | ) | | | | (93 | ) | | | | (2,110 | ) |
Income before provision for income taxes | | | 4,821 | | | | | 6,357 | | | | | 17,324 | | | | | 17,692 | |
| Provision for income taxes | | | 1,914 | | | | | 2,495 | | | | | 6,920 | | | | | 6,968 | |
Net income | | $ | 2,907 | | | | $ | 3,862 | | | | $ | 10,404 | | | | $ | 10,724 | |
| | | | | | | | | | | | | | | | | | | | |
| Net income attributable to common shares: | | | | | | | | | | | | | | | | | | | |
| Basic | | $ | 0.13 | | | | $ | 0.18 | | | | $ | 0.46 | | | | $ | 0.49 | |
| Diluted | | $ | 0.13 | | | | $ | 0.18 | | | | $ | 0.46 | | | | $ | 0.49 | |
| | | | | | | | | | | | | | | | | | | | |
| Weighted average common shares outstanding: | | | | | | | | | | | | | | | | | | | |
| Basic | | | 22,658,232 | | | | | 21,808,483 | | | | | 22,652,205 | | | | | 21,804,159 | |
| Diluted | | | 22,693,197 | | | | | 22,032,881 | | | | | 22,703,071 | | | | | 21,967,641 | |
| Segment information: | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | Three months ended September 30, | | Nine months ended September 30, |
| | 2008 | | 2007 | | 2008 | | 2007 |
| | | (unaudited) | | | | (unaudited) | |
| Net sales by segment | | | | | | | | | | | | | | | |
| Physician dispensed | | $ | 24,773 | | | | $ | 24,880 | | | | $ | 75,725 | | | | $ | 72,045 | |
| Pharmacy Rx | | | 25 | | | | | - | | | | | 25 | | | | | - | |
| Licensing | | | 1,214 | | | | | 1,401 | | | | | 3,408 | | | | | 3,349 | |
| Net sales | | $ | 26,012 | | | | $ | 26,281 | | | | $ | 79,158 | | | | $ | 75,394 | |
| Gross profit by segment | | | | | | | | | | | | | | | | | | | |
| Physician dispensed | | $ | 19,695 | | | | $ | 20,310 | | | | $ | 60,941 | | | | $ | 59,029 | |
| Pharmacy Rx | | | 22 | | | | | - | | | | | 22 | | | | | - | |
| Licensing | | | 1,181 | | | | | 1,367 | | | | | 3,307 | | | | | 3,240 | |
| Gross profit | | $ | 20,898 | | | | $ | 21,677 | | | | $ | 64,270 | | | | $ | 62,269 | |
| Geographic information | | | | | | | | | | | | | | | | | | | |
| United States | | $ | 21,743 | | | | $ | 22,155 | | | | $ | 66,510 | | | | $ | 63,685 | |
| International | | | 4,269 | | | | | 4,126 | | | | | 12,648 | | | | | 11,709 | |
| Net sales | | $ | 26,012 | | | | $ | 26,281 | | | | $ | 79,158 | | | | $ | 75,394 | |
| | | | | | | | | | | | | | | | | | | | |
| | Three months ended September 30, | | Nine months ended September 30, |
| | 2008 | | 2007 | | 2008 | | 2007 |
| | | (unaudited) | | | | (unaudited) | |
| Net sales by product line | | | | | | | | | | | | | | | | | | | |
| Physician dispensed | | | | | | | | | | | | | | | | | | | |
| Nu-Derm | | $ | 14,764 | | | | $ | 16,259 | | | | $ | 43,973 | | | | $ | 45,851 | |
| Vitamin C | | | 3,104 | | | | | 2,692 | | | | | 9,386 | | | | | 8,531 | |
| Elasticity | | | 2,399 | | | | | 1,646 | | | | | 9,502 | | | | | 6,077 | |
| Therapeutic | | | 1,780 | | | | | 1,812 | | | | | 4,689 | | | | | 4,219 | |
| Other | | | 2,726 | | | | | 2,471 | | | | | 8,175 | | | | | 7,367 | |
| Total | | | 24,773 | | | | | 24,880 | | | | | 75,725 | | | | | 72,045 | |
Pharmacy Rx | | | 25 | | | | | - | | | | | 25 | | | | | - | |
| Licensing | | | 1,214 | | | | | 1,401 | | | | | 3,408 | | | | | 3,349 | |
| Total net sales | | $ | 26,012 | | | | $ | 26,281 | | | | $ | 79,158 | | | | $ | 75,394 | |
